Cypherpunk Technologies (CYPH) closed at $1.93 on November 16, 2026, up 2.9% from the previous close, on volume of 10,983,635 shares (30-day average 12,962,781).
Data as of November 16, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 13, 2026 | Calendar Put Spread | 13-Nov : 04-Dec-26 2.5 P | 3,200 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the largest for 5, 30, 60 and 90 days
Cypherpunk Technologies Earnings Call Signals Zcash Growth
TipRanks (Mon, 16-Nov 7:05 PM ET)
Cypherpunk Technologies GAAP EPS of $1.13 beats by $1.09, revenue of $9.91M misses by $6.29M
Seeking Alpha News (Mon, 16-Nov 7:07 AM ET)
Cypherpunk Technologies Reports Third Quarter 2026 Financial Results
PRNewswire (Mon, 16-Nov 7:00 AM ET)
Here are the major earnings before the open Monday
Seeking Alpha News (Sat, 14-Nov 6:00 PM ET)
Cypherpunk Technologies Q3 Earnings Preview
Seeking Alpha News (Fri, 13-Nov 11:08 AM ET)
Cypherpunk Technologies to Report Third Quarter 2026 Financial Results on November 16, 2026
PRNewswire (Tue, 10-Nov 7:00 AM ET)
CYPH taps Amanda Fabiano for its board as Zcash mining posts 3,023.13 ZEC in its first weeks
Market Chameleon (Tue, 22-Sep 7:40 AM ET)
Cypherpunk Technologies Appoints Amanda Fabiano to Board of Directors
PRNewswire (Tue, 22-Sep 7:00 AM ET)
Cypherpunk Technologies Launches World's Largest Zcash Mining Fleet
PRNewswire (Tue, 18-Aug 7:00 AM ET)
Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.
Cypherpunk Technologies trades on the NASDAQ stock market under the symbol CYPH.
As of November 16, 2026, CYPH stock price climbed to $1.92 with 10,983,635 million shares trading.
CYPH has a beta of 1.17, meaning it tends to be more sensitive to market movements. CYPH has a correlation of 0.01 to the broad based SPY ETF.
CYPH has a market cap of $207.45 million. This is considered a Small Cap stock.
The top ETF exchange traded funds that CYPH belongs to (by Net Assets): VTI, VXF, DECO, AVSC, SATO.
CYPH has underperformed the market in the last year with a price return of +9.4% while the SPY ETF gained +11.2%. However, in the short term, CYPH had mixed performance relative to the market. It has outperformed in the last 3 months, returning +197.1% vs -4.6% return in SPY. But in the last 2 weeks, CYPH shares have been beat by the market, returning -35.4% compared to an SPY return of -2.1%.
CYPH support price is $1.67 and resistance is $2.07 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CYPH shares will trade within this expected range on the day.